HCP, INC. Form 10-Q August 02, 2013 Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the quarterly period ended June 30, 2013.
OR
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission file number 001-08895

	Edgar	Filing:	HCP,	INC.	- Form	10-Q
--	-------	---------	------	------	--------	------

HCP, INC.

(Exact name of registrant as specified in its charter)

Maryland

33-0091377 (I.R.S. Employer Identification No.)

(State or other jurisdiction of incorporation or organization)

> 3760 Kilroy Airport Way, Suite 300 Long Beach, CA 90806 (Address of principal executive offices)

(562) 733-5100 (Registrant s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). YES x NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer x

Accelerated Filer o

Non-accelerated Filer o (Do not check if a smaller reporting company) Smaller Reporting Company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) YES o NO x

As of July 25, 2013, there were 455,098,236 shares of the registrant s \$1.00 par value common stock outstanding.

Table of Contents

HCP, INC.

INDEX

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements:	
	Condensed Consolidated Balance Sheets	3
	Condensed Consolidated Statements of Income	4
	Condensed Consolidated Statements of Comprehensive Income	5
	Condensed Consolidated Statements of Equity	6
	Condensed Consolidated Statements of Cash Flows	7
	Notes to the Condensed Consolidated Financial Statements	8
Item 2.	Management s Discussion and Analysis of Financial Condition and Results of Operations	26
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	43
Item 4.	Controls and Procedures	44
	PART II. OTHER INFORMATION	
Item 1A.	Risk Factors	45
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	45
Item 6.	<u>Exhibits</u>	46
<u>Signatures</u>		47
	2	

HCP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

(Unaudited)

	June 30, 2013	D	December 31, 2012
ASSETS			
Real estate:			
Buildings and improvements	\$ 10,692,628	\$	10,522,399
Development costs and construction in progress	221,907		236,864
Land	1,852,768		1,847,928
Accumulated depreciation and amortization	(1,905,879)		(1,731,742)
Net real estate	10,861,424		10,875,449
Net investment in direct financing leases	6,958,129		6,881,393
Loans receivable, net	555,791		276,030
Investments in and advances to unconsolidated joint ventures	208,878		212,213
Accounts receivable, net of allowance of \$2,058 and \$1,668, respectively	33,270		34,150
Cash and cash equivalents	53,114		247,673
Restricted cash	44,953		37,848
Intangible assets, net	518,982		552,701
Real estate held for sale, net	6,936		9,578
Other assets, net	810,316		788,520
Total assets(1)	\$ 20,051,793	\$	19,915,555
LIABILITIES AND EQUITY			
Bank line of credit	\$ 261,582	\$	
Term loan	208,418		222,694
Senior unsecured notes	6,564,842		6,712,624
Mortgage debt	1,653,426		1,676,544
Other debt	78,633		81,958
Intangible liabilities, net	108,864		105,909
Accounts payable and accrued liabilities	313,627		293,994
Deferred revenue	64,142		68,055
Total liabilities(2)	9,253,534		9,161,778
Commitments and contingencies			
Common stock, \$1.00 par value: 750,000,000 shares authorized; 455,094,411 and			
453,191,321 shares issued and outstanding, respectively	455,094		453,191
Additional paid-in capital	11,254,658		11,180,066
Cumulative dividends in excess of earnings	(1,100,834)		(1,067,367)
Accumulated other comprehensive loss	(12,360)		(14,653)
Total stockholders equity	10,596,558		10,551,237
Joint venture partners	16,910		14,752
Non-managing member unitholders	184,791		187,788
Total noncontrolling interests	201,701		202,540
Total equity	10,798,259		10,753,777
Total liabilities and equity	\$ 20,051,793	\$	19,915,555

- (1) The Company's consolidated total assets at December 31, 2012, include assets of certain variable interest entities (VIEs) that can only be used to settle the liabilities of those VIEs as follows: accounts receivable, net, \$2 million; cash and cash equivalents, \$10 million; and other assets, net, \$2 million. See Note 16 to the Condensed Consolidated Financial Statements for additional information.
- (2) The Company's consolidated total liabilities at December 31, 2012, include liabilities of certain VIEs for which the VIE creditors do not have recourse to HCP, Inc. as follows: other debt, \$0.2 million; accounts payable and accrued liabilities, \$14 million; and deferred revenue, \$2 million. See Note 16 to the Condensed Consolidated Financial Statements for additional information.

See accompanying Notes to the Condensed Consolidated Financial Statements.

HCP, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data)

(Unaudited)

	Three Months Ended June 30, 2013 2012			Six Months Ended June 30, 2013 2012			me 30, 2012
Revenues:	2010		2012		2010		2012
Rental and related revenues	\$ 280,616	\$	244,603	\$	565,251	\$	484,859
Tenant recoveries	25,146		23,581		49,349		46,231
Resident fees and services	37,590		35,569		74,481		71,748
Income from direct financing leases	158,286		154,976		315,156		309,511
Interest income	14,147		1,216		26,533		2,035
Investment management fee income	499		470		942		963
Total revenues	516,284		460,415		1,031,712		915,347
Costs and expenses:							
Interest expense	108,716		102,354		218,006		206,044
Depreciation and amortization	110,686		84,873		215,314		170,062
Operating	74,814		70,076		148,419		137,409
General and administrative	24,073		14,801		44,744		34,884
Total costs and expenses	318,289		272,104		626,483		548,399
Other income, net	3,240		1,028		15,303		1,462
Income before income taxes and equity income from							
unconsolidated joint ventures	201,235		189,339		420,532		368,410
Income taxes	(1,654)		(171)		(2,530)		541
Equity income from unconsolidated joint ventures	15,585		15,732		30,386		29,407
Income from continuing operations	215,166		204,900		448,388		398,358
Discontinued operations:							
Income before gain on sales of real estate	672		75		1,234		325
Gain on sales of real estate	887				887		2,856
Total discontinued operations	1,559		75		2,121		3,181
Net income	216,725		204,975		450,509		401,539
Noncontrolling interests share in earnings	(3,324)		(2,951)		(6,523)		(6,135)
Net income attributable to HCP, Inc.	213,401		202,024		443,986		395,404
Preferred stock dividends							(17,006)
Participating securities share in earnings	(378)		(557)		(856)		(1,674)
Net income applicable to common shares	\$ 213,023	\$	201,467	\$	443,130	\$	376,724
Basic earnings per common share:							
Continuing operations	\$ 0.47	\$	0.48	\$	0.97	\$	0.90
Discontinued operations					0.01		0.01
Net income applicable to common shares	\$ 0.47	\$	0.48	\$	0.98	\$	0.91
Diluted earnings per common share:							
Continuing operations	\$ 0.47	\$	0.48	\$	0.97	\$	0.90
Discontinued operations							

Edgar Filing: HCP, INC. - Form 10-Q

Net income applicable to common shares	\$ 0.47	\$ 0.48 \$	0.97	\$ 0.90
Weighted average shares used to calculate earnings per				
common share:				
Basic	454,618	420,468	454,137	415,243
Diluted	455,431	421,671	455,024	416,666
Dividends declared per common share	\$ 0.525	\$ 0.50 \$	1.05	1.00

See accompanying Notes to the Condensed Consolidated Financial Statements.

HCP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

(Unaudited)

	Three Months I 2013	June 30, 2012	Six Months Er 2013	une 30, 2012		
Net income	\$ 216,725	\$	204,975 \$	450,509	\$	401,539
Other comprehensive income (loss):						
Unrealized gains on securities:						
Unrealized gains (losses)			(961)	1,355		343
Reclassification adjustment realized in net income				(9,131)		
Change in net unrealized gains on cash flow hedges:						
Unrealized gains (losses)	4,025		(1,056)	9,345		(780)
Reclassification adjustment realized in net income	288		90	560		179
Change in Supplemental Executive Retirement Plan						
obligation	55		45	111		90
Foreign currency translation adjustment	(125)		(155)	53		47
Total other comprehensive income (loss)	4,243		(2,037)	2,293		(121)
Total comprehensive income	220,968		202,938	452,802		401,418
Total comprehensive income attributable to noncontrolling						
interests	(3,324)		(2,951)	(6,523)		(6,135)
Total comprehensive income attributable to HCP, Inc.	\$ 217,644	\$	199,987 \$	446,279	\$	395,283

 $See\ accompanying\ Notes\ to\ the\ Condensed\ Consolidated\ Financial\ Statements.$

HCP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(In thousands, except per share data)

(Unaudited)

					Cı	umulative	Ac	cumulated				
				Additional	D	Dividends		Other	Total		Total	
	Comm	non S	tock	Paid-In	I	n Excess	Con	nprehensive S	tockholders	Nor	controlling	Total
	Shares	A	mount	Capital	Of	f Earnings	Inc	ome (Loss)	Equity]	Interests	Equity
January 1, 2013	453,191	\$	453,191	\$ 11,180,066	\$ ((1,067,367))\$	(14,653)\$	10,551,237	\$	202,540 \$	10,753,777
Net income						443,986			443,986		6,523	450,509
Other comprehensive income								2,293	2,293			2,293
Issuance of common stock, net	1,097		1,097	49,221					50,318		(2,997)	47,321
Repurchase of common stock	(46)		(46)	(2,224)					(2,270)		(2,270)
Exercise of stock options	852		852	15,957					16,809			16,809
Amortization of deferred												
compensation				11,638					11,638			11,638
Common dividends (\$1.05 per												
share)						(477,453))		(477,453)		(477,453)
Distributions to noncontrolling												
interests											(7,506)	(7,506)
Issuance of noncontrolling												
interests											3,141	3,141
June 30, 2013	455,094	\$	455,094	\$ 11,254,658	\$ ((1,100,834))\$	(12,360)\$	10,596,558	\$	201,701 \$	10,798,259

		red Stock		non Stock	Addition Paid-In	al Dividends In Excess	Accumulated Other Comprehensiv&			Total
T 1 2012	Shares	Amount	Shares	Amount	Capital		Income (Loss)	Equity	Interests	Equity
January 1, 2012	11,820	\$ 285,173	408,629	\$ 408,629	\$ 9,383,	536 \$ (1,024,27				
Net income						395,40	4	395,404	6,135	401,539
Other										
comprehensive							(121)	(101)		(121)
loss							(121)	(121)		(121)
Preferred stock	(11.020)	(205 172)				(10.22	7)	(205 500)		(205 500)
redemption Issuance of	(11,820)	(285,173)				(10,32	/)	(295,500)		(295,500)
common stock,			18,912	10.012	727	1.45		756 057	(2.272)	752 794
net Damumahasa af			18,912	18,912	737,	143		756,057	(2,273)	753,784
Repurchase of common stock			(190)	(190	(7.	(70)		(7.967)		(7.967)
Exercise of stock			(189)	(189)) (7,	678)		(7,867)		(7,867)
options			2,050	2,050	35,	170		37,220		37,220
Amortization of			2,030	2,030	33,	170		31,220		31,220
deferred										
compensation					11,	107		11,407		11,407
Preferred					11,	+0 /		11,407		11,407
dividends						(6,67	0)	(6,679)		(6,679)
Common						(416,17	1	(416,173)		(416,173)
dividends (\$1.00						(410,17	3)	(410,173)		(410,173)

Edgar Filing: HCP, INC. - Form 10-Q

per share)								
Distributions to								
noncontrolling								
interests							(7,778)	(7,778)
Issuance of								
noncontrolling								
interests							873	873
Purchase of								
noncontrolling								
interests							(388)	(388)
June 30, 2012	\$ 429,402	\$ 429,402	\$ 10,159,580	\$ (1,062,049)\$	(19,703)\$	9,507,230 \$	183,709 \$	9,690,939

See accompanying Notes to the Condensed Consolidated Financial Statements.

HCP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands) (Unaudited)

Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization of real estate, in-place lease and other intangibles:		Six Months Ended June 30,			
Net income \$ 450,509 \$ 401,539 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization of real estate, in-place lease and other intangibles: Jone of the properations 215,314 170,062 6,138 Amortization of dependences 1,100 6,138 Amortization of above and below market lease intangibles, net (6,068) 11,232 Amortization of deferred compensation 1,168 11,400 8,459 11,232 Amortization of deferred financing costs, net 9,440 8,459 8,459 11,609 11,		2013		2012	
Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization of real estate, in-place lease and other intangibles:	Cash flows from operating activities:				
Depreciation and amortization of real estate, in-place lease and other intangibles: 215,314 170,06 Continuing operations 170 6,138 Amortization of above and below market lease intangibles, net (6,068) (1,322) Amortization of deferred financing costs, net 9,440 8,459 Straight-line rents (15,955) (21,787) Loan and direct financing lease interest accretion (45,539) (48,159) Deferred rental revenues (965) 1,169 Eguity income from unconsolidated joint ventures (30,386) (29,407) Distributions of earnings from unconsolidated joint ventures (30,386) (29,407) Gain on sales of real estate (887) (2,886) Marketable securities gain on sales, net (10,977) (50 Foreign currency and derivative (gains) losses, net 462 708 Changes in: 462 708 Changes in: 462 708 Characteristic gain on sales, net 462 708 Characteristic gain on sales, net 462 708 Other assets 12,253 (8,188) <td>Net income</td> <td>\$ 450,509</td> <td>\$</td> <td>401,539</td>	Net income	\$ 450,509	\$	401,539	
Continuing operations 215.314 170,062 Discontinued operations 170 6,138 Amortization of above and below market lease intangibles, net (6,068) (1,322) Amortization of deferred compensation 11,638 11,407 Amortization of deferred compensation 11,638 11,407 Amortization of deferred funcing costs, net 49,400 8,459 Straight-line rents (15,955) (21,787) Loan and direct financing lease interest accretion (45,539) (48,159) Deferred rental revenues (965) 1,169 Equity income from unconsolidated joint ventures (30,386) (29,407) Distributions of earnings from unconsolidated joint ventures (1,624) 1,878 Gain on sales of real estate (887) (2,856) Marketable securities gain on sales, net (10,977) Foreign currency and derivative (gains) losses, net 780 (52) Changes in: 462 708 Accounts receivable, net 462 708 Other assets (12,852) (8,188) Net cash provide	Adjustments to reconcile net income to net cash provided by operating activities:				
Discontinued operations 170 6.138 Amortization of above and below market lease intangibles, net (6,068) (1,322) Amortization of deferred compensation 11,638 11,407 Amortization of deferred financing costs, net 9,440 8,459 Straight-line rents (15,955) (21,875) Loan and direct financing lease interest accretion (45,539) (48,159) Deferred rental revenues (965) 1,169 Eguity income from unconsolidated joint ventures (30,386) (29,407) Distributions of earnings from unconsolidated joint ventures (10,977) (2,856) Marketable securities gain on sales, net (10,977) (2,856) Other assets (2,828) (3,888) (2,818)					
Amortization of above and below market lease intangibles, net (6,068) (1,322) Amortization of deferred compensation 11,638 11,407 Amortization of deferred financing costs, net 9,440 8,459 Straight-line rents (15,555) (21,787) Loan and direct financing lease interest accretion (45,539) (48,159) Deferred rental revenues (965) 1,169 Equity income from unconsolidated joint ventures (30,386) (29,407) Distributions of earnings from unconsolidated joint ventures 1,624 1,878 Gain on sales of real estate (887) (2,856) Marketable securities gain on sales, net (10,977) Foreign currency and derivative (gains) losses, net 780 (52) Changes in: 462 708 Accounts receivable, net 462 708 Other assets (12,852) (8,188) Accounts payable and accrued liabilities 5,294 (6,038) Net cash provided by operating activities 5,294 (6,038) Accust payable and accrued liabilities (60,353) (10,970)		215,314		170,062	
Amortization of deferred compensation 11,638 11,407 Amortization of deferred financing costs, net 9,440 8,459 Straight-line rents (15,955) (21,787) Loan and direct financing lease interest accretion (45,539) (48,159) Deferred rental revenues (965) 1,169 Equity income from unconsolidated joint ventures (30,386) (29,407) Distributions of earnings from unconsolidated joint ventures (16,24) 1,878 Gain on sales of real estate (887) (2,856) Marketable securities gain on sales, net (10,977) (52) Foreign currency and derivative (gains) losses, net 70 (52) Changes in: 86 (20,806) (30,806) (29,407) Accounts receivable, net 462 708 (52) (52) (52) Chear saces (12,852) (8,88) Accounts payable and accrued liabilities 5,294 (6,038) Net cash provided by operating activities 51,062 483,551 Cash flows from investing activities (60,353) (10,970) <t< td=""><td>Discontinued operations</td><td>170</td><td></td><td>6,138</td></t<>	Discontinued operations	170		6,138	
Amortization of deferred financing costs, net 9,440 8,589 Straight-line rents (15,555) (21,787) Loan and direct financing lease interest accretion (45,539) (48,159) Deferred rental revenues (965) 1,169 Equity income from unconsolidated joint ventures (30,386) (29,407) Distributions of earnings from unconsolidated joint ventures 1,624 1,878 Gain on sales of real estate (887) (28,56) Marketable securities gain on sales, net (10,977) Foreign currency and derivative (gains) losses, net 780 (52) Changes in: 462 708 Accounts receivable, net 462 708 Other assets (12,852) (8,188) Accounts payable and accrued liabilities 5,294 (6,038) Accounts provided by operating activities 571,602 483,51 Cash flows from investing activities 6(0,353) (10,970) Development of real estate (60,353) (10,970) Development of real estate (60,353) (27,112) Proceeds from	Amortization of above and below market lease intangibles, net	(6,068)		(1,322)	
Straight-line rents (15,955) (21,787) Loan and direct financing lease interest accretion (45,539) (48,159) Deferred rental revenues (965) 1,169 Equity income from unconsolidated joint ventures (30,386) (29,407) Distributions of earnings from unconsolidated joint ventures (887) (2,856) Gain on sales of real estate (887) (2,856) Marketable securities gain on sales, net (10,977) Foreign currency and derivative (gains) losses, net 780 (52) Changes in: 780 (52) Changes in: 462 708 Other assets (12,852) (8,188) Accounts payable and accrued liabilities 5,294 (6,038) Accounts payable and accrued liabilities 5,294 (6,038) Net cash provided by operating activities 51,602 483,551 Cash flows from investing activities (60,353) (10,970) Development of real estate (60,353) (10,970) Development of real estate, net (79,983) (27,112) Proceeds from sales of	Amortization of deferred compensation	11,638			
Loan and direct financing lease interest accretion (45,539) (48,159) Deferred rental revenues (965) 1,169 Equity in come from unconsolidated joint ventures (30,386) (29,407) Distributions of earnings from unconsolidated joint ventures 1,624 1,878 Gain on sales of real estate (887) (2,856) Marketable securities gain on sales, net (10,977) Foreign currency and derivative (gains) losses, net 780 (52) Changes in: 462 708 Accounts receivable, net 462 708 Other assets (12,852) (8,188) Accounts payable and accrued liabilities 5,294 (6,038) Net cash provided by operating activities 571,602 483,551 Cabilition of real estate (60,353) (10,970) Development of real estate (67,983) (51,890) Leasing costs and tenant and capital improvements (96,983) (51,890) Leasing costs and tenant and capital improvements (90,403) (21,859) Distributions in excess of earnings from unconsolidated joint ventures 904	Amortization of deferred financing costs, net	9,440			
Deferred rental revenues (965) 1,169 Equity income from unconsolidated joint ventures 30,386 (29,407) Distributions of earnings from unconsolidated joint ventures 1,624 1,878 Gain on sales of real estate (887) (2,856) Marketable securities gain on sales, net (10,977) 780 (52) Foreign currency and derivative (gains) losses, net	Straight-line rents	(15,955)		(21,787)	
Equity income from unconsolidated joint ventures (30,386) (29,407) Distributions of earnings from unconsolidated joint ventures 1,624 1,878 Gain on sales of real estate (887) (2,856) Marketable securities gain on sales, net (10,977) Foreign currency and derivative (gains) losses, net 780 (52) Changes in:	Loan and direct financing lease interest accretion	(45,539)		(48,159)	
Distributions of earnings from unconsolidated joint ventures 1,624 1,878 Gain on sales of real estate (887) (2,856) Marketables securities gain on sales, net (10,977) Foreign currency and derivative (gains) losses, net 780 (52) Changes in: 462 708 Accounts receivable, net 462 708 Other assets (12,852) (8,188) Accounts payable and accrued liabilities 5,294 (6,038) Net cash provided by operating activities 571,602 483,551 Cash flows from investing activities (60,353) (10,970) Development of real estate (67,983) (51,890) Leasing costs and tenant and capital improvements (19,938) (27,112) Proceeds from sales of real estate, net 3,777 7,238 Distributions in excess of earnings from unconsolidated joint ventures 904 1,529 Purchases of marketable debt securities 28,030 19112 4,508 Inversas in restricted cash (30,673) (20,757) (1,526) (14,859) Pricicipal repayments	Deferred rental revenues	(965)		1,169	
Gain on sales of real estate (887) (2,856) Marketable securities gain on sales, net (10,977) (52) Changes in: (2,856) (32) (32) Accounts receivable, net 462 708 (32) (8,188) Accounts payable and accrued liabilities 5,294 (6,038) (6,038) (6,038) (8,188) Accounts payable and accrued liabilities 5,294 (6,038) Accounts payable and accrued liabilities 5,294 (6,038) Accounts payable and accrued liabilities 5,294 (6,038) Accounts payable and accrued liabilities 6,038 Accounts payable and accrued liabilities 6,18,00 Account	Equity income from unconsolidated joint ventures	(30,386)		(29,407)	
Marketable securities gain on sales, net (10,977) Foreign currency and derivative (gains) losses, net 780 (52) Changes in:	Distributions of earnings from unconsolidated joint ventures	1,624		1,878	
Foreign currency and derivative (gains) losses, net 780 (52) Changes in: 462 708 Other assets (12,852) (8,188) Accounts payable and accrued liabilities 5,294 (6,038) Net cash provided by operating activities 571,602 483,551 Cash flows from investing activities: W Acquisitions of real estate (60,353) (10,970) Development of real estate (67,983) (51,890) Leasing costs and tenant and capital improvements (19,938) (27,112) Proceeds from sales of real estate, net 3,777 7,238 Distributions in excess of earnings from unconsolidated joint ventures 904 1,529 Purchases of marketable debt securities 16,706 (24,859) Proceeds from the sale of marketable securities 28,030 V Principal repayments on loans receivable 19,112 4,508 Investments in loans receivable (300,673) (20,757) Increase in restricted cash (7,105) (1,229) Net cash used in investing activities 420,093 (313,542) <td>Gain on sales of real estate</td> <td>(887)</td> <td></td> <td>(2,856)</td>	Gain on sales of real estate	(887)		(2,856)	
Changes in: Accounts receivable, net 462 708 Accounts resets (12,852) (8,188) Accounts payable and accrued liabilities 5,294 (6,038) Net cash provided by operating activities 571,602 483,551 Cash flows from investing activities 571,602 483,551 Caquisitions of real estate (60,353) (10,970) Development of real estate (67,983) (51,890) Leasing costs and tenant and capital improvements (19,938) (27,112) Proceeds from sales of real estate, net 3,777 7,238 Distributions in excess of earnings from unconsolidated joint ventures 904 1,529 Proceeds from sales of real estate, net (16,706) (214,859) Purchases of marketable debt securities 904 1,529 Proceeds from the sale of marketable securities 28,030 Proceeds from the sale of marketable securities 28,030 Proceeds from the sale of marketable securities (300,673) (20,757) Increase in restricted cash (7,105) (1,229) Net zeash used in investing activities 265,049	Marketable securities gain on sales, net	(10,977)			
Accounts receivable, net 462 708 Other assets (12,852) (8,188) Accounts payable and accrued liabilities 5,294 (6,038) Net cash provided by operating activities 571,602 483,551 Cash flows from investing activities: 8 Acquisitions of real estate (60,353) (10,970) Development of real estate (67,983) (51,890) Leasing costs and tenant and capital improvements (19,938) (27,112) Proceeds from sales of real estate, net 3,777 7,238 Distributions in excess of earnings from unconsolidated joint ventures 904 1,529 Purchases of marketable debt securities (16,706) (214,859) Proceeds from the sale of marketable securities 28,030 Principal repayments on loans receivable 19,112 4,508 Investments in loans receivable (300,673) (20,757) Increase in restricted cash (7,105) (1,229) Net cash used in investing activities 420,935 (313,542) Cash flows from financing activities 265,049 (238,985) Issu	Foreign currency and derivative (gains) losses, net	780		(52)	
Other assets (12,852) (8,188) Accounts payable and accrued liabilities 5,294 (6,038) Net cash provided by operating activities 571,602 483,551 Cash flows from investing activities: ************************************	Changes in:				
Accounts payable and accrued liabilities 5,294 (6,038) Net cash provided by operating activities 571,602 483,551 Cash flows from investing activities: 8 Acquisitions of real estate (60,353) (10,970) Development of real estate (67,983) (51,890) Leasing costs and tenant and capital improvements (19,938) (27,112) Proceeds from sales of real estate, net 3,777 7,238 Distributions in excess of earnings from unconsolidated joint ventures 904 1,529 Purchases of marketable debt securities (16,706) (214,859) Proceeds from the sale of marketable securities 28,030 (20,757) Proceeds from the sale of marketable securities 28,030 (20,757) Proceeds from the sale of marketable securities 45,08 Investments in loans receivable (300,673) (20,757) Increase in restricted cash (7,105) (12,229) Net cash used in investing activities (420,935) (313,542) Cash flows from financing activities 265,049 (238,985) Issuance of senior unsecured notes	Accounts receivable, net	462		708	
Net cash provided by operating activities 571,602 483,551 Cash flows from investing activities: (60,353) (10,970) Development of real estate (67,983) (51,890) Leasing costs and tenant and capital improvements (19,938) (27,112) Proceeds from sales of real estate, net 3,777 7,238 Distributions in excess of earnings from unconsolidated joint ventures 904 1,529 Purchases of marketable debt securities (16,706) (214,859) Proceeds from the sale of marketable securities 28,030 *** Principal repayments on loans receivable (300,673) (20,757) Increase in restricted cash (7,105) (1,229) Net cash used in investing activities (7,105) (1,229) Vet cash flows from financing activities 265,049 (238,985) Issuance of senior unsecured notes 450,000 (250,000) Repayments of senior unsecured notes (40,380) (42,538) Deferred financing costs (40,380) (42,538) Deferred stock redemption (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137	Other assets	(12,852)		(8,188)	
Cash flows from investing activities: Acquisitions of real estate (60,353) (10,970) Development of real estate (67,983) (51,890) Leasing costs and tenant and capital improvements (19,938) (27,112) Proceeds from sales of real estate, net 3,777 7,238 Distributions in excess of earnings from unconsolidated joint ventures 904 1,529 Purchases of marketable debt securities (16,706) (214,859) Proceeds from the sale of marketable securities 28,030 Principal repayments on loans receivable 19,112 4,508 Investments in loans receivable (300,673) (20,757) Increase in restricted cash (7,105) (1,229) Net cash used in investing activities (420,935) (313,542) Cash flows from financing activities (420,935) (313,542) Cash flows from financing activities 265,049 (238,985) Issuance of senior unsecured notes (50,000) (250,000) Repayments of mortgage debt (40,380) (42,538) Deferred financing costs (10,236) (295,500) Preferred stock redemption (19,500) (295,5	Accounts payable and accrued liabilities	5,294		(6,038)	
Acquisitions of real estate (60,353) (10,970) Development of real estate (67,983) (51,890) Leasing costs and tenant and capital improvements (19,938) (27,112) Proceeds from sales of real estate, net 3,777 7,238 Distributions in excess of earnings from unconsolidated joint ventures 904 1,529 Purchases of marketable debt securities (16,706) (214,859) Proceeds from the sale of marketable securities 28,030 Principal repayments on loans receivable 19,112 4,508 Investments in loans receivable (300,673) (20,757) Increase in restricted cash (7,105) (1,229) Net cash used in investing activities (420,935) (313,542) Cash flows from financing activities 265,049 (238,985) Issuance of senior unsecured notes 450,000 (250,000) Repayments of senior unsecured notes (150,000) (250,000) Repayments of mortgage debt (40,380) (42,538) Deferred financing costs (10,236) (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 <tr< td=""><td>Net cash provided by operating activities</td><td>571,602</td><td></td><td>483,551</td></tr<>	Net cash provided by operating activities	571,602		483,551	
Development of real estate (67,983) (51,890) Leasing costs and tenant and capital improvements (19,938) (27,112) Proceeds from sales of real estate, net 3,777 7,238 Distributions in excess of earnings from unconsolidated joint ventures 904 1,529 Purchases of marketable debt securities 904 1,529 Proceeds from the sale of marketable securities 28,030 Principal repayments on loans receivable 19,112 4,508 Investments in loans receivable (300,673) (20,757) Increase in restricted cash (7,105) (1,229) Net cash used in investing activities (420,935) (313,542) Cash flows from financing activities 265,049 (238,985) Issuance of senior unsecured notes 450,000 (250,000) Repayments of senior unsecured notes (150,000) (250,000) Repayments of mortgage debt (40,380) (42,538) Deferred financing costs (10,236) Preferred stock redemption (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 <td>Cash flows from investing activities:</td> <td></td> <td></td> <td></td>	Cash flows from investing activities:				
Leasing costs and tenant and capital improvements (19,938) (27,112) Proceeds from sales of real estate, net 3,777 7,238 Distributions in excess of earnings from unconsolidated joint ventures 904 1,529 Purchases of marketable debt securities (16,706) (214,859) Proceeds from the sale of marketable securities 28,030 Principal repayments on loans receivable 19,112 4,508 Investments in loans receivable (300,673) (20,757) Increase in restricted cash (7,105) (1,229) Net cash used in investing activities (420,935) (313,542) Cash flows from financing activities (420,935) (338,985) Issuance of senior unsecured notes 450,000 (238,985) Issuance of senior unsecured notes (150,000) (250,000) Repayments of mortgage debt (40,380) (42,538) Deferred financing costs (10,236) Preferred stock redemption (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 Dividends paid on common and preferred stock (4	Acquisitions of real estate	(60,353)		(10,970)	
Proceeds from sales of real estate, net 3,777 7,238 Distributions in excess of earnings from unconsolidated joint ventures 904 1,529 Purchases of marketable debt securities (16,706) (214,859) Proceeds from the sale of marketable securities 28,030 Principal repayments on loans receivable 19,112 4,508 Investments in loans receivable (300,673) (20,757) Increase in restricted cash (7,105) (1,229) Net cash used in investing activities (420,935) (313,542) Cash flows from financing activities (420,935) (338,985) Issuance of senior unsecured notes 56,049 (238,985) Issuance of senior unsecured notes (150,000) (250,000) Repayments of senior unsecured notes (150,000) (250,000) Repayments of mortgage debt (40,380) (42,388) Deferred financing costs (10,236) Preferred stock redemption (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 Dividends paid on common and preferred stock (477,453)	Development of real estate	(67,983)		(51,890)	
Distributions in excess of earnings from unconsolidated joint ventures 904 1,529 Purchases of marketable debt securities (16,706) (214,859) Proceeds from the sale of marketable securities 28,030 Principal repayments on loans receivable 19,112 4,508 Investments in loans receivable (300,673) (20,757) Increase in restricted cash (7,105) (1,229) Net cash used in investing activities (420,935) (313,542) Cash flows from financing activities: 265,049 (238,985) Issuance of senior unsecured notes 450,000 (250,000) Repayments of senior unsecured notes (150,000) (250,000) Repayments of mortgage debt (40,380) (42,538) Deferred financing costs (10,236) Preferred stock redemption (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 Dividends paid on common and preferred stock (477,453) (422,852) Issuance of noncontrolling interests 3,141 873	Leasing costs and tenant and capital improvements	(19,938)		(27,112)	
Purchases of marketable debt securities (16,706) (214,859) Proceeds from the sale of marketable securities 28,030 Principal repayments on loans receivable 19,112 4,508 Investments in loans receivable (300,673) (20,757) Increase in restricted cash (7,105) (1,229) Net cash used in investing activities (420,935) (313,542) Cash flows from financing activities: *** *** Net borrowings (repayments) under bank line of credit 265,049 (238,985) Issuance of senior unsecured notes (150,000) (250,000) Repayments of mortgage debt (40,380) (42,538) Deferred financing costs (40,380) (42,538) Preferred stock redemption (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 Dividends paid on common and preferred stock (477,453) (422,852) Issuance of noncontrolling interests 3,141 873	Proceeds from sales of real estate, net	3,777		7,238	
Proceeds from the sale of marketable securities 28,030 Principal repayments on loans receivable 19,112 4,508 Investments in loans receivable (300,673) (20,757) Increase in restricted cash (7,105) (1,229) Net cash used in investing activities (420,935) (313,542) Cash flows from financing activities: 8 (420,935) (238,985) Issuance of senior unsecured notes 450,000 (238,985) Issuance of senior unsecured notes (150,000) (250,000) Repayments of mortgage debt (40,380) (42,538) Deferred financing costs (10,236) Preferred stock redemption (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 Dividends paid on common and preferred stock (477,453) (422,852) Issuance of noncontrolling interests 3,141 873	Distributions in excess of earnings from unconsolidated joint ventures	904		1,529	
Principal repayments on loans receivable 19,112 4,508 Investments in loans receivable (300,673) (20,757) Increase in restricted cash (7,105) (1,229) Net cash used in investing activities (420,935) (313,542) Cash flows from financing activities: 8 (420,935) (238,985) Issuance of senior unsecured notes 265,049 (238,985) Issuance of senior unsecured notes (150,000) (250,000) Repayments of mortgage debt (40,380) (42,538) Deferred financing costs (10,236) Preferred stock redemption (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 Dividends paid on common and preferred stock (477,453) (422,852) Issuance of noncontrolling interests 3,141 873	Purchases of marketable debt securities	(16,706)		(214,859)	
Investments in loans receivable (300,673) (20,757) Increase in restricted cash (7,105) (1,229) Net cash used in investing activities (420,935) (313,542) Cash flows from financing activities: 265,049 (238,985) Net borrowings (repayments) under bank line of credit 265,049 (238,985) Issuance of senior unsecured notes (150,000) (250,000) Repayments of senior unsecured notes (40,380) (42,538) Deferred financing costs (10,236) Preferred stock redemption (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 Dividends paid on common and preferred stock (477,453) (422,852) Issuance of noncontrolling interests 3,141 873	Proceeds from the sale of marketable securities	28,030			
Increase in restricted cash (7,105) (1,229) Net cash used in investing activities (420,935) (313,542) Cash flows from financing activities: 265,049 (238,985) Net borrowings (repayments) under bank line of credit 265,049 (238,985) Issuance of senior unsecured notes (150,000) (250,000) Repayments of senior unsecured notes (40,380) (42,538) Deferred financing costs (10,236) Preferred stock redemption (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 Dividends paid on common and preferred stock (477,453) (422,852) Issuance of noncontrolling interests 3,141 873	Principal repayments on loans receivable	19,112		4,508	
Net cash used in investing activities (420,935) (313,542) Cash flows from financing activities: (238,985) Net borrowings (repayments) under bank line of credit 265,049 (238,985) Issuance of senior unsecured notes 450,000 Repayments of senior unsecured notes (150,000) (250,000) Repayments of mortgage debt (40,380) (42,538) Deferred financing costs (10,236) Preferred stock redemption (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 Dividends paid on common and preferred stock (477,453) (422,852) Issuance of noncontrolling interests 3,141 873	Investments in loans receivable	(300,673)		(20,757)	
Cash flows from financing activities: Net borrowings (repayments) under bank line of credit 265,049 (238,985) Issuance of senior unsecured notes 450,000 Repayments of senior unsecured notes (150,000) (250,000) Repayments of mortgage debt (40,380) (42,538) Deferred financing costs (10,236) Preferred stock redemption (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 Dividends paid on common and preferred stock (477,453) (422,852) Issuance of noncontrolling interests 3,141 873	Increase in restricted cash	(7,105)		(1,229)	
Net borrowings (repayments) under bank line of credit 265,049 (238,985) Issuance of senior unsecured notes 450,000 Repayments of senior unsecured notes (150,000) (250,000) Repayments of mortgage debt (40,380) (42,538) Deferred financing costs (10,236) Preferred stock redemption (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 Dividends paid on common and preferred stock (477,453) (422,852) Issuance of noncontrolling interests 3,141 873	Net cash used in investing activities	(420,935)		(313,542)	
Issuance of senior unsecured notes 450,000 Repayments of senior unsecured notes (150,000) (250,000) Repayments of mortgage debt (40,380) (42,538) Deferred financing costs (10,236) Preferred stock redemption (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 Dividends paid on common and preferred stock (477,453) (422,852) Issuance of noncontrolling interests 3,141 873	Cash flows from financing activities:				
Repayments of senior unsecured notes (150,000) (250,000) Repayments of mortgage debt (40,380) (42,538) Deferred financing costs (10,236) Preferred stock redemption (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 Dividends paid on common and preferred stock (477,453) (422,852) Issuance of noncontrolling interests 3,141 873	Net borrowings (repayments) under bank line of credit	265,049		(238,985)	
Repayments of mortgage debt (40,380) (42,538) Deferred financing costs (10,236) Preferred stock redemption (295,500) Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 Dividends paid on common and preferred stock (477,453) (422,852) Issuance of noncontrolling interests 3,141 873	Issuance of senior unsecured notes			450,000	
Deferred financing costs(10,236)Preferred stock redemption(295,500)Net proceeds from the issuance of common stock and exercise of options61,860783,137Dividends paid on common and preferred stock(477,453)(422,852)Issuance of noncontrolling interests3,141873	Repayments of senior unsecured notes	(150,000)		(250,000)	
Deferred financing costs(10,236)Preferred stock redemption(295,500)Net proceeds from the issuance of common stock and exercise of options61,860783,137Dividends paid on common and preferred stock(477,453)(422,852)Issuance of noncontrolling interests3,141873	Repayments of mortgage debt	(40,380)		(42,538)	
Preferred stock redemption(295,500)Net proceeds from the issuance of common stock and exercise of options61,860783,137Dividends paid on common and preferred stock(477,453)(422,852)Issuance of noncontrolling interests3,141873	Deferred financing costs			(10,236)	
Net proceeds from the issuance of common stock and exercise of options 61,860 783,137 Dividends paid on common and preferred stock (477,453) (422,852) Issuance of noncontrolling interests 3,141 873	Preferred stock redemption			(295,500)	
Dividends paid on common and preferred stock (477,453) (422,852) Issuance of noncontrolling interests 3,141 873		61,860			
Issuance of noncontrolling interests 3,141 873		(477,453)		(422,852)	
	Issuance of noncontrolling interests	3,141			
	Distributions to noncontrolling interests	(7,506)		(7,778)	

Edgar Filing: HCP, INC. - Form 10-Q

Net cash used in financing activities	(345,289)	(33,879)
Effect of foreign exchange on cash and cash equivalents	63	
Net increase (decrease) in cash and cash equivalents	(194,559)	136,130
Cash and cash equivalents, beginning of period	247,673	33,506
Cash and cash equivalents, end of period	\$ 53,114	\$ 169,636

See accompanying Notes to the Condensed Consolidated Financial Statements.

Table of Contents

HCP, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(1) Business

HCP, Inc., an S&P 500 company, together with its consolidated entities (collectively, HCP or the Company), invests primarily in real estate serving the healthcare industry in the United States (U.S.). The Company is a Maryland corporation and was organized to qualify as a self-administered real estate investment trust (REIT) in 1985. The Company is headquartered in Long Beach, California, with offices in Nashville, Tennessee and San Francisco, California. The Company acquires, develops, leases, manages and disposes of healthcare real estate, and provides financing to healthcare providers. The Company s portfolio is comprised of investments in the following five healthcare segments: (i) senior housing, (ii) post-acute/skilled nursing, (iii) life science, (iv) medical office and (v) hospital. The Company makes investments within the healthcare segments using the following five investment products: (i) properties under lease, (ii) debt investments, (iii) developments and redevelopments, (iv) investment management and (v) investments in senior housing operations utilizing the structure permitted by the Housing and Economic Recovery Act of 2008, which is commonly referred to as RIDEA.

(2) Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. Management is required to make estimates and assumptions in the preparation of financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from management s estimates.

The condensed consolidated financial statements include the accounts of HCP, Inc., its wholly-owned subsidiaries and joint ventures or variable interest entities (VIEs) that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company's financial position, results of operations and cash flows have been included. Operating results for the six months ended June 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. The accompanying unaudited interim financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2012 included in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the SEC).

Certain amounts in the Company s condensed consolidated financial statements have been reclassified for prior periods to conform to the current period presentation. Assets sold or held for sale and associated liabilities have been reclassified on the condensed consolidated balance sheets

8
In July 2012, the FASB issued Accounting Standards Update No. 2012-01, <i>Continuing Care Retirement Communities Refundable Advance Fees</i> (ASU 2012-01). This update clarifies the situations in which recognition of deferred revenue for refundable advance fees is appropriate. The adoption of ASU 2012-01 on January 1, 2013 did not have a material impact on the Company s consolidated financial position or results of operations.
In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (ASU 2013-02). This update requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income. The adoption of ASU 2013-02 on January 1, 2013 did not have a material impact on the Company s consolidated financial position or results of operations.
Recent Accounting Pronouncements
Transaction costs related to acquisitions of businesses, including properties, are expensed as incurred.
Acquisition Costs
and the related operating results reclassified from continuing to discontinued operations on the condensed consolidated statements of income (see Note 4).

m 1	1	c	\sim		
Tab	uе	ΩŤ	('0	nte	ntc

(3)	Real Estate Property	Investments
-----	----------------------	-------------

\$1.73 Billion Senior Housing Portfolio Acquisition (the Blackstone JV Acquisition)

During the fourth quarter of 2012 and first quarter of 2013, the Company acquired 133 senior housing communities for \$1.73 billion from a joint venture between Emeritus Corporation (Emeritus) and Blackstone Real Estate Partners VI, an affiliate of the Blackstone Group (the Blackstone JV). Located in 29 states, the portfolio encompasses a diversified care mix of 61% assisted living, 25% independent living, 13% memory care and 1% skilled nursing based on units. Based on operating performance at closing, the 133 communities consisted of 99 that were stabilized and 34 that were in lease-up. The transaction closed in two stages: (i) 129 senior housing facilities during the fourth quarter of 2012 for \$1.7 billion; and (ii) four senior housing facilities during the first quarter of 2013 for \$38 million. The Company paid \$1.73 billion in cash consideration and assumed \$13 million of mortgage debt to acquire: (i) real estate with a fair value of \$1.57 billion, (ii) intangible assets with a fair value of \$174 million; and (iii) assumed intangible liabilities with a fair value of \$4 million. As of June 30, 2013, the purchase price allocation is preliminary, and the final purchase price allocation will be determined pending the receipt of information necessary to complete the valuation of certain assets and liabilities, which may result in changes from the initial estimates.

Emeritus operates the communities pursuant to a new triple-net master lease for 128 properties (the Master Lease) and five individual leases, all guaranteed by Emeritus (together, the Leases). The Leases provide aggregate contractual rent in the first year of \$105.8 million. The contractual rent will increase annually by the greater of the percentage increase in the Consumer Price Index (CPI) or 3.7% on average over the initial five years, and thereafter by the greater of CPI or 3.0% for the remaining initial lease term. At the beginning of the sixth lease year, rent on the 34 lease-up properties will increase to the greater of the percentage increase in CPI or fair market, subject to a floor of 103% and a cap of 130% of the prior year s rent.

The Master Lease properties are grouped into three pools that share comparable characteristics. The Leases have initial terms of 14 to 16 years. Emeritus has two extension options, which, if exercised, will provide for lease terms of 30 to 35 years.

Concurrent with the acquisition in 2012, Emeritus purchased nine communities from the Blackstone JV, for which the Company provided secured debt financing of \$52 million with a four-year term. The loan is secured by the underlying real estate and is prepayable at Emeritus option. The interest rate on the loan was initially 6.1% and will gradually increase during its four year term to 6.8%.

Pro Forma Results of Operations

The following unaudited pro forma consolidated results of operations assume that the Blackstone JV Acquisition was completed as of January 1, 2012 (in thousands, except per share amounts):

Three Months Ended June 30, 2012 Six Months Ended June 30, 2012

Edgar Filing: HCP, INC. - Form 10-Q

Revenues	\$ 486,865 \$	968,247
Net income	212,380	416,349
Net income applicable to HCP, Inc.	209,429	410,214
Basic earnings per common share	0.47	0.90
Diluted earnings per common share	0.47	0.90

Other Real Estate Acquisitions

In addition to the Blackstone JV Acquisition (discussed above), during the six months ended June 30, 2013, the Company acquired a senior housing facility for \$18 million, exercised its purchase option for a senior housing facility it previously leased for \$16 million and acquired 38 acres of land in the post-acute/skilled nursing segment for \$408,000.

During the six months ended June 30, 2012, the Company acquired a life science facility for \$8 million and 13 acres of land in the hospital segment for \$3 million.

During the six months ended June 30, 2013 and 2012, the Company funded an aggregate of \$76 million and \$79 million, respectively, for construction, tenant and other capital improvement projects, primarily in its senior housing, life science and medical office segments.

(4) Dispositions of Real Estate and Discontinued Operations

During the six months ended June 30, 2013, the Company sold a senior housing facility for \$4 million. During the six months ended June 30, 2012, the Company sold a medical office building for \$7 million.

At June 30, 2013, one hospital was classified as held for sale, with a carrying value of \$7 million. At December 31, 2012, properties classified as held for sale included a senior housing facility and hospital with a combined aggregate carrying value of \$10 million.

The following table summarizes operating loss from discontinued operations and gain on sales of real estate included in discontinued operations (dollars in thousands):

	Three Months 2013	Ended	June 30, 2012	Six Months En	ine 30, 2012	
Rental and related revenues	\$ 779	\$	4,024	\$ 1,620	\$	8,349
Depreciation and amortization expenses	81		3,051	170		6,138
Operating expenses			11			29
Other expense, net	26		887	216		1,857
Income before gain on sales of real estate	\$ 672	\$	75	\$ 1,234	\$	325
Gain on sales of real estate, net of income taxes	\$ 887	\$		\$ 887	\$	2,856
Number of properties included in discontinued						
operations	2		5	2		6

(5) Net Investment in Direct Financing Leases

The components of net investment in direct financing leases (DFLs) consisted of the following (dollars in thousands):

	June 30, 2013	December 31, 2012
Minimum lease payments receivable(1)	\$ 24,948,287	\$ 25,217,520
Estimated residual values	4,010,514	4,010,514
Less unearned income	(22,000,672)	(22,346,641)
Net investment in direct financing leases	\$ 6,958,129	\$ 6,881,393
Properties subject to direct financing leases	361	361

(1) The minimum lease payments receivable are primarily attributable to HCR ManorCare, Inc. (HCR ManorCare) (\$23.8 billion and \$24.0 billion at June 30, 2013 and December 31, 2012, respectively). The triple-net master lease with HCR ManorCare provides for annual rent of \$506 million beginning April 1, 2013 (prior to April 1, 2013, annual rent was \$489 million). The rent increases by 3.5% per year over the next three years and by 3% for the remaining portion of the initial lease term. The properties are grouped into four pools, and HCR ManorCare has a one-time extension option for each pool with rent increased for the first year of the extension option to the greater of fair market rent or a 3% increase over the rent for the prior year. Including the extension options, which the Company determined to be bargain renewal options, the four leased pools had total initial available terms ranging from 23 to 35 years.

Certain leases contain provisions that allow the tenants to elect to purchase the properties during or at the end of the lease terms for the aggregate initial investment amount plus adjustments, if any, as defined in the lease agreements. Certain leases also permit the Company to require the tenants to purchase the properties at the end of the lease terms.

(6) Loans Receivable

The following table summarizes the Company s loans receivable (in thousands):

	al Estate ecured	_	ne 30, 2013 Other Secured	Total	Real Estate Secured	Dece	ember 31, 2012 Other Secured	Total
Mezzanine	\$	\$	428,723	\$ 428,723	\$	\$	145,150	\$ 145,150
Other	161,957			161,957	147,264			147,264
Unamortized discounts, fees and								
costs			(21,479)	(21,479)			(2,974)	(2,974)
Allowance for loan losses			(13,410)	(13,410)			(13,410)	(13,410)
	\$ 161,957	\$	393,834	\$ 555,791	\$ 147,264	\$	128,766	\$ 276,030

Barchester Loan

On May 2, 2013, the Company acquired £121 million of subordinated debt at a discount for £109 million. The loan is secured by an interest in 160 facilities leased and operated by Barchester Healthcare (Barchester). This loan matures in September 2013 and bears interest on its face value at a floating rate of London Interbank Offered Rate (LIBOR) plus a weighted-average margin of 3.14%. At June 30, 2013, the carrying value of this loan was \$165 million. This loan investment was financed by a GBP denominated draw on the Company s revolving line of credit facility that is discussed in Note 10.

Tandem Health Care Loan

On July 31, 2012, the Company closed a mezzanine loan facility to lend up to \$205 million to Tandem Health Care (Tandem), an affiliate of Formation Capital, as part of the recapitalization of a post-acute/skilled nursing portfolio. At closing, the loan was subordinate to \$400 million in senior mortgage debt and \$137 million in senior mezzanine debt. The Company funded \$100 million (the First Tranche) at closing and funded an additional \$102 million (the Second Tranche) in June 2013. The Second Tranche was used to repay the senior mezzanine debt. At June 30, 2013, the loan was subordinate to \$444 million of senior mortgage debt. The loan bears interest at a fixed rate of 12% and 14% per annum for the First and Second Tranches, respectively. The facility has a total term of up to 63 months from the initial closing, is prepayable at the borrower s option and is secured by real estate partnership interests. The loan is subject to a prepayment premium if repaid on or before the third anniversary from the initial closing date.

Delphis Operations, L.P. Loan

The Company holds a secured term loan made to Delphis Operations, L.P. (Delphis or the Borrower) that is collateralized by all of the assets of the Borrower. The Borrower s collateral is comprised primarily of interests in partnerships operating surgical facilities, some of which are on the premises of properties owned by the Company or HCP Ventures IV, LLC, an unconsolidated joint venture of the Company. In December 2009,

the Company determined that the loan was impaired. Further, in January 2011 the Company placed the loan on cost-recovery status, whereby accrual of interest income was suspended and any payments received from the Borrower are applied to reduce the recorded investment in the loan.

As part of a March 2012 agreement (the 2012 Agreement) between Delphis, certain past and current principals of Delphis and the Cirrus Group, LLC (the Guarantors), and the Company, the Company agreed, among other things, to allow the distribution of \$1.5 million to certain of the Guarantors from funds generated from sales of assets that were pledged as additional collateral for this loan. Further, the Company, as part of the 2012 Agreement, agreed to provide financial incentives to the Borrower regarding the liquidation of the primary collateral assets for this loan.

Pursuant to the 2012 Agreement, the Company received the remaining cash (\$4.8 million, after reducing this amount by \$0.5 million for related legal expenses) and other consideration (\$2.1 million) of \$6.9 million from the Guarantors. In addition, during 2012 the Company received \$38.1 million in net proceeds from the sales of two of the primary collateral assets, which proceeds, together with the cash payments and other consideration, were applied to reduce the carrying value of the loan. The carrying value of the loan was \$29.2 million and \$30.7 million at June 30, 2013 and December 31, 2012, respectively. During the three and six months ended June 30, 2013, the Company received cash payments from the Borrower of \$1.5 million. At June 30, 2013, the Company believes the fair value of the collateral supporting this loan is in excess of its carrying value.

(7) Investments in and Advances to Unconsolidated Joint Ventures

The Company owns interests in the following entities that are accounted for under the equity method at June 30, 2013 (dollars in thousands):

Entity(1)	Properties/Segment	Inv	vestment(2)	Ownership%
HCR ManorCare	post-acute/skilled nursing operations	\$	88,018	9.5(3)
HCP Ventures III, LLC	13 medical office		7,335	30
HCP Ventures IV, LLC	54 medical office and 4 hospital		31,049	20
HCP Life Science(4)	4 life science		68,779	50-63
Horizon Bay Hyde Park, LLC	1 senior housing		6,496	72
Suburban Properties, LLC	1 medical office		6,950	67
Advances to unconsolidated joint ventures, net			251	
		\$	208,878	
Edgewood Assisted Living Center, LLC	1 senior housing	\$	(387)	45
Seminole Shores Living Center, LLC	1 senior housing		(634)	50
	_	\$	(1,021)	

⁽¹⁾ These entities are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.

Summarized combined financial information for the Company s unconsolidated joint ventures follows (in thousands):

	June 30, 2013	December 31, 2012
Real estate, net	\$ 3,690,920	\$ 3,731,740
Goodwill and other assets, net	5,807,180	5,734,318
Total assets	\$ 9,498,100	\$ 9,466,058
Capital lease obligations and mortgage debt	\$ 6,813,884	\$ 6,875,932
Accounts payable	1,047,460	971,095
Other partners capital	1,452,467	1,435,885
HCP s capital(1)	184,289	183,146
Total liabilities and partners capital	\$ 9,498,100	\$ 9,466,058

⁽²⁾ Represents the carrying value of the Company s investment in the unconsolidated joint venture.

⁽³⁾ Presented after adjusting the Company s 9.9% ownership for the dilution of certain of HCR ManorCare s outstanding employee equity awards.

⁽⁴⁾ Includes three unconsolidated joint ventures between the Company and an institutional capital partner for which the Company is the managing member. HCP Life Science includes the following partnerships: (i) Torrey Pines Science Center, LP (50%); (ii) Britannia Biotech Gateway, LP (55%); and (iii) LASDK, LP (63%).

(1) The combined basis difference of the Company s investments in these joint ventures of \$23 million, as of June 30, 2013, is primarily attributable to goodwill, real estate, capital lease obligations, deferred tax assets and lease related net intangibles.

	Three Months	Ended	June 30,	Six Months E	Ended June 30,			
	2013		2012	2013		2012		
Total revenues	\$ 1,059,412	\$	1,093,873	\$ 2,152,863	\$	2,138,519		
Net income	10,122		16,124	20,494		17,267		
HCP s share in earning(1)	15,585		15,732	30,386		29,407		
Fees earned by HCP	499		470	942		963		
Distributions received by HCP	1,157		1,278	2,528		3,407		

⁽¹⁾ The Company s joint venture interest in HCR ManorCare is accounted for using the equity method and results in an ongoing reduction of DFL income, proportional to HCP s ownership in HCR ManorCare. The Company recorded a reduction of \$15 million for both the three months ended June 30, 2013 and 2012. The Company recorded a reduction of \$31 million and \$30 million for the six months ended June 30, 2013 and 2012, respectively. Further, the Company s share of earnings from HCR ManorCare (equity income) increases for the corresponding reduction of related lease expense recognized at the HCR ManorCare level.

(8) Intangibles

At both June 30, 2013 and December 31, 2012, intangible lease assets, comprised of lease-up intangibles, above market tenant lease intangibles and below market ground lease intangibles, were \$794 million. At June 30, 2013 and December 31, 2012, the accumulated amortization of intangible assets was \$275 million and \$241 million, respectively.

At June 30, 2013 and December 31, 2012, intangible lease liabilities, comprised of below market lease intangibles and above market ground lease intangible liabilities were \$215 and \$199 million, respectively. At June 30, 2013 and December 31, 2012, the accumulated amortization of intangible liabilities was \$106 million and \$93 million, respectively.

(9) Other Assets

The Company s other assets consisted of the following (in thousands):

	June 30, 2013	December 31, 2012
Straight-line rent assets, net of allowance of \$34,147 and \$33,521, respectively	\$ 339,464	\$ 306,294
Marketable debt securities(1)	225,285	222,809
Leasing costs, net	98,408	93,763
Deferred financing costs, net	39,986	45,490
Goodwill	50,346	50,346
Marketable equity securities		24,829
Other(2)	56,827	44,989
Total other assets	\$ 810,316	\$ 788,520

⁽¹⁾ Includes £136.9 million (\$208 million and \$223 million at June 30, 2013 and December 31, 2012, respectively) of Four Seasons senior unsecured notes translated into U.S. dollars (see below for additional information).

During the six months ended June 30, 2013, the Company realized gains from the sale of marketable equity securities of \$11 million, which were included in other income, net. At December 31, 2012, the fair value and adjusted cost basis of the marketable equity securities were \$24.8 million and \$17.1 million, respectively. The marketable equity securities were classified as available-for-sale.

⁽²⁾ Includes a \$5.4 million allowance for losses related to accrued interest receivable on the Delphis loan, which accrued interest is included in other assets. At both June 30, 2013 and December 31, 2012, the carrying value of interest accrued related to the Delphis loan was zero. See Note 6 for additional information about the Delphis loan and the related impairment. At both June 30, 2013 and December 31, 2012, includes a loan receivable of \$10 million from HCP Ventures IV, LLC, an unconsolidated joint venture (see Note 7 for additional information) with an interest rate of 12% which matures in May 2014. The loan is secured by HCP s joint venture partner s 80% partnership interest in the joint venture.

Four Seasons Health Care Senior Unsecured Notes

On June 28, 2012, the Company purchased senior unsecured notes with an aggregate par value of £138.5 million at a discount for £136.8 million (\$214.9 million). The notes were issued by Elli Investments Limited, a subsidiary of Terra Firma, a European private equity firm, as part of its financing for the acquisition of Four Seasons Health Care (Four Seasons), an elderly and specialist care provider in the United Kingdom. The notes mature in June 2020 and are non-callable through June 2016. The notes bear interest on their par value at a fixed rate of 12.25% per annum, with an original issue discount resulting in a yield to maturity of 12.5%. This investment was financed by a GBP denominated unsecured term loan that is discussed in Note 10. These senior unsecured notes are accounted for as marketable debt securities and classified as held-to-maturity.

(10) Debt

Bank Line of Credit and Term Loan

The Company s \$1.5 billion unsecured revolving line of credit facility (the Facility) matures in March 2016 and contains a one-year extension option. Borrowings under the Facility accrue interest at LIBOR plus a margin that depends on the Company s debt ratings. The Company pays a facility fee on the entire revolving commitment that depends upon its debt ratings. Based on the Company s debt ratings at June 30, 2013, the margin on the Facility was 1.075%, and the facility fee was 0.175%. The Facility also includes a feature that will allow the Company to increase the borrowing capacity by an aggregate amount of up to \$500 million, subject to securing additional commitments from existing lenders or new lending institutions. At June 30, 2013, the Company had \$262 million (includes £109 million translated into U.S. dollars) outstanding under the Facility.

Table of Contents

On July 30, 2012, the Company entered into a credit agreement with a syndicate of banks for a £137 million (\$208 million at June 30, 2013) four-year unsecured term loan (the Term Loan) that accrues interest at a rate of GBP LIBOR plus 1.20%, based on the Company s current debt ratings. Concurrent with the closing of the Term Loan, the Company entered into a four-year interest rate swap contract that fixes the interest rate of the Term Loan at 1.81%, subject to adjustments based on the Company s debt ratings. The Term Loan contains a one-year committed extension option.

The Facility and Term Loan contain certain financial restrictions and other customary requirements, including cross-default provisions to other indebtedness. Among other things, these covenants, using terms defined in the agreements, (i) limit the ratio of Consolidated Total Indebtedness to Consolidated Total Asset Value to 60%, (ii) limit the ratio of Secured Debt to Consolidated Total Asset Value to 30%, (iii) limit the ratio of Unsecured Debt to Consolidated Unencumbered Asset Value to 60%, (iv) require a minimum Fixed Charge Coverage ratio of 1.5 times and (v) require a formula-determined Minimum Consolidated Tangible Net Worth of \$9.2 billion at June 30, 2013. At June 30, 2013, the Company was in compliance with each of these restrictions and requirements of the Facility and Term Loan.

Senior Unsecured Notes

At June 30, 2013, the Company had senior unsecured notes outstanding with an aggregate principal balance of \$6.6 billion. At June 30, 2013, interest rates on the notes ranged from 1.24% to 6.98% with a weighted average effective interest rate of 5.10% and a weighted average maturity of six years. Discounts and premiums are amortized to interest expense over the term of the related senior unsecured notes. The senior unsecured notes contain certain covenants including limitations on debt, cross-acceleration provisions and other customary terms. The Company believes it was in compliance with these covenants at June 30, 2013.

On February 28, 2013, the Company repaid \$150 million of maturing 5.625% senior unsecured notes.

On November 19, 2012, the Company issued \$800 million of 2.625% senior unsecured notes due in 2020. The notes were priced at 99.7% of the principal amount with an effective yield to maturity of 2.7%; net proceeds from this offering were \$793 million.

On July 23, 2012, the Company issued \$300 million of 3.15% senior unsecured notes due in 2022. The notes were priced at 98.9% of the principal amount with an effective yield to maturity of 3.3%; net proceeds from the offering were \$294 million.

On June 25, 2012, the Company repaid \$250 million of maturing 6.45% senior unsecured notes. The senior unsecured notes were repaid with proceeds from the Company s June 2012 common stock offering.

On January 23, 2012, the Company issued \$450 million of 3.75% senior unsecured notes due in 2019. The notes were priced at 99.5% of the principal amount with an effective yield to maturity of 3.8%; net proceeds from the offering were \$444 million.

Mortgage Debt

At June 30, 2013, the Company had \$1.7 billion in aggregate principal amount of mortgage debt outstanding that is secured by 138 healthcare facilities (including redevelopment properties) with a carrying value of \$2.1 billion. At June 30, 2013, interest rates on the mortgage debt ranged from 0.69% to 8.69% with a weighted average effective interest rate of 6.12% and a weighted average maturity of three years.

Mortgage debt generally requires monthly principal and interest payments, is collateralized by real estate assets and is generally non-recourse. Mortgage debt typically restricts transfer of the encumbered assets, prohibits additional liens, restricts prepayment, requires payment of real estate taxes, requires maintenance of the assets in good condition, requires maintenance on the assets and includes conditions to obtain lender consent to enter into or terminate material leases. Some of the mortgage debt is also cross-collateralized by multiple assets and may require tenants or operators to maintain compliance with the applicable leases or operating agreements of such real estate assets.

Other Debt

At June 30, 2013, the Company had \$79 million of non-interest bearing life care bonds at two of its continuing care retirement communities and non-interest bearing occupancy fee deposits at two of its senior housing facilities, all of which were payable to certain residents of the facilities (collectively, Life Care Bonds). The Life Care Bonds are refundable to the residents upon the termination of the contract or upon the successful resale of the unit.

Debt Maturities

The following table summarizes the Company s stated debt maturities and scheduled principal repayments at June 30, 2013 (in thousands):

Year	Line of Credit(1)	Tern	n Loan(2)	Senior Unsecured Notes	Mortgage Debt	Total(3)
2013 (Six months)	\$	\$		\$ 400,000	\$ 254,973 \$	6	54,973
2014				487,000	180,221	6	67,221
2015				400,000	308,611	7	08,611
2016	261,582		208,418	900,000	291,941	1,6	61,941
2017				750,000	550,788	1,3	00,788
Thereafter				3,650,000	73,468	3,7	23,468
	261,582		208,418	6,587,000	1,660,002	8,7	17,002
(Discounts) and premiums, net				(22,158)	(6,576)	(28,734)
	\$ 261.582	\$	208,418	\$ 6,564,842	\$ 1.653.426 \$	8.6	88.268

⁽¹⁾ Includes £109 million translated into U.S. dollars.

(11) Commitments and Contingencies

Legal Proceedings

From time to time, the Company is a party to legal proceedings, lawsuits and other claims that arise in the ordinary course of the Company s business. The Company is not aware of any legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company s business, prospects, financial condition, results of operations or cash flows. The Company s policy is to expense

⁽²⁾ Represents £137 million translated into U.S. dollars.

⁽³⁾ Excludes \$79 million of other debt that represents the Life Care Bonds that have no scheduled maturities.

legal costs as they are incurred.

Concentration of Credit Risk

Concentrations of credit risks arise when a number of operators, tenants or obligors related to the Company s investments are engaged in similar business activities, or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to the Company, to be similarly affected by changes in economic conditions. The Company regularly monitors various segments of its portfolio to assess potential concentrations of risks. The Company does not have significant foreign operations.

The following table provides information regarding the Company s concentrations with respect to certain operators and tenants; the information provided is presented for the gross assets and revenues that are associated with certain operators and tenants as percentages of the respective segment s and total Company s gross assets and revenues:

Segment Concentrations:

	Percentage Senior Housing Gr		Percentag Senior Housing	,	Percentage of Senior Housing Revenues				
	June 30,	31,	Three Months En	- /	Six Months Ended June 30,				
Operators	2013	2012	2013	2012	2013	2012			
Emeritus	35%	35%	35%	23%	35%	21%			
Sunrise Senior Living									
(Sunrise)(1)	17	17	13	17	13	16			
HCR ManorCare	11	11	9	13	9	12			
Brookdale Senior Living (Brookdale)(2)	10	11	11	16	12	14			

	Percentage of Po Skilled Nursing G		Percentage of I Skilled Nursing		Percentage of Post-Acute/ Skilled Nursing Revenues					
	June 30,	31,	Three Months Er	ided June 30,	Six Months End	led June 30,				
Operators	2013	2012	2013	2012	2013	2012				
HCR ManorCare	86%	89%	86%	93%	86%	93%				

Total Company Concentrations:

	Percentage Total Company G		Percentag Total Company	,	Percentage of Total Company Revenues					
Operators	June 30, 2013	31, 2012	Three Months End 2013	ded June 30, 2012	Six Months End 2013	ed June 30, 2012				
HCR ManorCare	32%	31%	28%	31%	28%	31%				
Emeritus	14	13	13	7	13	7				
Sunrise(1)	7	7	5	5	5	5				
Brookdale(2)	4	4	4	5	4	5				

⁽¹⁾ Certain of the Company s properties are leased to tenants who have entered into management contracts with Sunrise to operate the respective property on their behalf. The Company s concentration of gross assets includes properties directly leased to Sunrise and properties that are managed by Sunrise on behalf of third party tenants.

At June 30, 2013 and December 31, 2012, Brookdale percentages exclude \$705 million and \$692 million, respectively, of senior housing assets related to 21 senior housing facilities that Brookdale operates on the Company s behalf under a RIDEA structure. Assuming that these assets were attributable to Brookdale, the percentage of segment assets for Brookdale would be 19% and 20% at June 30, 2013 and December 31, 2012, respectively. Assuming that these assets were attributable to Brookdale, the percentage of total assets for Brookdale would be 8% at both June 30, 2013 and December 31, 2012. For the three and six months ended June 30, 2013, Brookdale percentages exclude \$37.6 million and \$74.4 million, respectively, of senior housing revenues related to these facilities. Assuming that these revenues were attributable to Brookdale, the percentage of segment revenues for Brookdale would be 31% for both the three and six months ended June

30, 2013. Assuming that these revenues were attributable to Brookdale, the percentage of total revenues for Brookdale would be 12% and 11%, respectively, for the three and six months ended June 30, 2013. For the three and six months ended June 30, 2012, Brookdale percentages exclude \$35.6 million and \$70.7 million, respectively, of senior housing revenues related to these facilities. Assuming that these revenues were attributable to Brookdale, the percentage of segment revenues for Brookdale would be 42% and 38% for the three and six months ended June 30, 2012, respectively. Assuming that these revenues were attributable to Brookdale, the percentage of total revenues for Brookdale would be 12% for both the three and six months ended June 30, 2012.

HCR ManorCare s summarized condensed consolidated financial information follows (in millions):

	June 30, 2013	December 31, 2012
Real estate and other property, net	\$ 3,019.9	\$ 3,046.6
Cash and cash equivalents	161.5	120.5
Goodwill, intangible and other assets, net	5,566.9	5,625.4
Total assets	\$ 8,748.3	\$ 8,792.5
Debt and financing obligations	\$ 6,319.0	\$ 6,374.6
Accounts payable, accrued liabilities and other	1,011.8	1,021.9
Total equity	1,417.5	1,396.0
Total liabilities and equity	\$ 8,748.3	\$ 8,792.5

		Three Months l	Ended	June 30,	Six Months Ended June 30,					
		2013		2012	2013		2012			
Revenues	\$	1.032.7	\$	1,034.3 \$	2.101.4	\$	2,075.5			
Operating, general and administrative	Ψ	1,032.7	Ψ	1,054.5 ψ	2,101.4	Ψ	2,013.3			
expense		(876.9)		(897.5)	(1,789.3)		(1,782.9)			
Depreciation and amortization expense		(36.4)		(41.6)	(73.7)		(83.6)			
Interest expense		(104.1)		(105.8)	(208.5)		(212.1)			
Other income (expense), net		(0.5)		3.1	1.7		6.4			
•										
Income (loss) before income taxes		14.8		(7.5)	31.6		3.3			
Income taxes		(4.7)		4.6	(9.8)		0.1			
Net income (loss)	\$	10.1	\$	(2.9) \$	21.8	\$	3.4			

To mitigate the credit risk of leasing properties to certain senior housing and post-acute/skilled nursing operators, leases with operators are often combined into portfolios that contain cross-default terms, so that if a tenant of any of the properties in a portfolio defaults on its obligations under its lease, the Company may pursue its remedies under the lease with respect to any of the properties in the portfolio. Certain portfolios also contain terms whereby the net operating profits of the properties are combined for the purpose of securing the funding of rental payments due under each lease.

Credit Enhancement Guarantee

Certain of the Company s senior housing facilities serve as collateral for \$114 million of debt (maturing May 1, 2025) that is owed by a previous owner of the facilities. This indebtedness is guaranteed by the previous owner who has an investment grade credit rating. These senior housing facilities, which are classified as DFLs, had a carrying value of \$377 million as of June 30, 2013.

(12) Equity

Preferred Stock

On April 23, 2012, the Company redeemed all of its outstanding preferred stock consisting of 4,000,000 shares of its 7.25% Series E preferred stock and 7,820,000 shares of its 7.10% Series F preferred stock. The shares of Series E and Series F preferred stock were redeemed at a price of \$25 per share, or \$295.5 million in aggregate, plus all accrued and unpaid dividends to the redemption date. As a result of the redemption, which was announced on March 22, 2012, the Company incurred a charge of \$10.4 million during the three months ended March 31, 2012 related to the original issuance costs of the preferred stock (this charge is presented as an additional preferred stock dividend in the Company s condensed consolidated statements of income).

Common Stock

The following table lists the common stock cash dividends declared by the Company in 2013:

		Amount	Dividend
Declaration Date	Record Date	Per Share	Payable Date
January 24	February 4	\$ 0.525	February 19
April 25	May 6	0.525	May 21
July 25	August 5	0.525	August 20

In October 2012, the Company completed a \$979 million offering of 22 million shares of common stock at a price of \$44.50, which proceeds were primarily used to fund the Blackstone JV Acquisition.

In June 2012, the Company completed a \$376 million offering of 8.97 million shares of common stock at a price of \$41.88 per share, which proceeds were primarily used to repay \$250 million of maturing senior unsecured notes.

In March 2012, the Company completed a \$359 million offering of 9.0 million shares of common stock at a price of \$39.93 per share, which proceeds were primarily used to redeem all outstanding shares of the Company s preferred stock.

The following is a summary of the Company s other common stock issuances (shares in thousands):

	Six Months Ended	June 30,
	2013	2012
Dividend Reinvestment and Stock Purchase Plan	925	501
Conversion of DownREIT units(1)	85	67
Exercise of stock options	852	2,050
Vesting of restricted stock units(2)	103	378

- (1) Non-managing member LLC units.
- (2) Issued under the Company s 2006 Performance Incentive Plan.

Accumulated Other Comprehensive Loss

The following is a summary of the Company s accumulated other comprehensive loss (in thousands):

	June 30, 2013	December 31, 2012
Unrealized gains on available for sale securities	\$ \$	7,776
Unrealized losses on cash flow hedges, net	(8,547)	(18,452)
Supplemental Executive Retirement Plan minimum liability	(3,039)	(3,150)
Cumulative foreign currency translation adjustment	(774)	(827)
Total accumulated other comprehensive loss	\$ (12,360) \$	(14,653)

Noncontrolling Interests

At June 30, 2013, there were four million DownREIT units outstanding in four LLCs, for which the Company is the managing member. At June 30, 2013, the carrying and fair values of these DownREIT units were \$185 million and \$273 million, respectively.

(13) Segment Disclosures

The Company evaluates its business and makes resource allocations based on its five business segments: (i) senior housing, (ii) post-acute/skilled nursing, (iii) life science, (iv) medical office and (v) hospital. Under the senior housing, post-acute/skilled nursing, life science and hospital segments, the Company invests or co-invests primarily in single operator or tenant properties, through the acquisition and development of real estate and by debt issued by operators in these sectors. Under the medical office segment, the Company invests or co-invests through the acquisition and development of medical office buildings (MOBs) that are leased under gross, modified gross or triple-net leases,

generally to multiple tenants, and which generally require a greater level of property management. The accounting policies of the segments are the same as those described in Note 2 to the Consolidated Financial Statements for the year ended December 31, 2012 in the Company s Annual Report on Form 10-K filed with the SEC. There were no intersegment sales or transfers during the six months ended June 30, 2013 and 2012. The Company evaluates performance based upon property net operating income from continuing operations (NOI), adjusted NOI and interest income of the combined investments in each segment.

Non-segment assets consist primarily of corporate assets including cash, restricted cash, accounts receivable, net, marketable equity securities, deferred financing costs and, if any, real estate held-for-sale. Interest expense, depreciation and amortization and non-property specific revenues and expenses are not allocated to individual segments in determining the Company s performance measure. See Note 11 for other information regarding concentrations of credit risk.

Summary information for the reportable segments follows (in thousands):

For the three months ended June 30, 2013:

		Rental	Re	sident Fees	Interest	Investr Manage		Total			Adjusted NOI(2)
Segments	Re	venues(1)	an	d Services	Income	Fee Inc	come	Revenues	NOI(2)	((Cash NOI)
Senior housing	\$	150,261	\$	37,590	\$ 2,806	\$		\$ 190,657	\$ 163,714	\$	148,400
Post-acute/skilled		137,520			11,029			148,549	136,867		120,128
Life science		75,227					1	75,228	61,388		58,265
Medical office		90,174					498	90,672	54,956		53,857
Hospital		10,866			312			11,178	9,899		21,609
Total	\$	464,048	\$	37,590	\$ 14,147	\$	499	\$ 516,284	\$ 426,824	\$	402,259

For the three months ended June 30, 2012:

		Rental	Re	sident Fees	Interest	Investme Managem		Total			Adjusted NOI(2)
Segments	Re	venues(1)	an	d Services	Income	Fee Incor	me	Revenues	NOI(2)	((Cash NOI)
Senior housing	\$	113,387	\$	35,569	\$ 527	\$		\$ 149,483	\$ 125,516	\$	113,936
Post-acute/skilled		134,353			427			134,780	134,188		116,517
Life science		72,545					1	72,546	58,990		55,735
Medical office		80,905				4	469	81,374	48,926		47,682
Hospital		21,970			262			22,232	21,033		20,509
Total	\$	423,160	\$	35,569	\$ 1,216	\$ 4	470	\$ 460,415	\$ 388,653	\$	354,379

For the six months ended June 30, 2013:

		Rental	Re	sident Fees	Interest	Invest Manag	tment gement	Total			djusted NOI(2)
Segments	Re	venues(1)	an	d Services	Income	Fee Ir	come	Revenues	NOI(2)	(C	ash NOI)
Senior housing	\$	299,157	\$	74,481	\$ 5,207	\$		\$ 378,845	\$ 325,110	\$	291,398
Post-acute/skilled		273,623			21,014			294,637	272,323		236,286
Life science		148,557					2	148,559	121,335		114,605
Medical office		177,429					940	178,369	107,915		105,528
Hospital		30,990			312			31,302	29,135		40,389
Total	\$	929,756	\$	74,481	\$ 26,533	\$	942	\$ 1,031,712	\$ 855,818	\$	788,206

For the six months ended June 30, 2012:

Edgar Filing: HCP, INC. - Form 10-Q

						T					Adjusted
		Rental	Re	sident Fees	Interest	Investmer Manageme		Total			NOI(2)
Segments	Re	venues(1)	ar	nd Services	Income	Fee Incom	ıe	Revenues	NOI(2)	(Cash NOI)
Senior housing	\$	226,692	\$	71,748	\$ 809	\$		\$ 299,249	\$ 253,386	\$	228,393
Post-acute/skilled		268,026			707			268,733	267,661		229,365
Life science		144,375					2	144,377	117,936		114,838
Medical office		160,861				9	61	161,822	97,178		94,604
Hospital		40,647			519			41,166	38,779		37,702
Total	\$	840,601	\$	71,748	\$ 2,035	\$ 9	63	\$ 915,347	\$ 774,940	\$	704,902

⁽¹⁾ Represents rental and related revenues, tenant recoveries and income from DFLs.

NOI is a non-GAAP supplemental financial measure used to evaluate the operating performance of real estate. The Company defines NOI as rental and related revenues, including tenant recoveries, resident fees and services, and income from direct financing leases, less property level operating expenses. NOI excludes interest income, investment management fee income, interest expense, depreciation and amortization, general and administrative expenses, litigation settlement, impairments, impairment recoveries, other income, net, income taxes, equity income from and impairments of investments in unconsolidated joint ventures, and discontinued operations. The Company believes NOI provides relevant and useful information because it reflects only income and operating expense items that are incurred at the property level and presents them on an unleveraged basis. Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL accretion, amortization of above and below market lease intangibles, and lease termination fees. Adjusted NOI is sometimes referred to as cash NOI. The Company uses NOI and adjusted NOI to make decisions about resource allocations and to assess and compare property level performance. The Company believes that net income is the most directly comparable GAAP measure to NOI. NOI should not be viewed as an alternative measure of operating performance to net income as defined by GAAP because it does not reflect the aforementioned excluded items. Further, the Company s definition of NOI may not be comparable to the definition used by other REITs or real estate companies, as those companies may use different methodologies for calculating NOI.

The following is a reconciliation of reported net income to NOI and adjusted NOI (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,		
	2013		2012		2013		2012
Net income	\$ 216,725	\$	204,975	\$	450,509	\$	401,539
Interest income	(14,147)		(1,216)		(26,533)		(2,035)
Investment management fee income	(499)		(470)		(942)		(963)
Interest expense	108,716		102,354		218,006		206,044
Depreciation and amortization	110,686		84,873		215,314		170,062
General and administrative	24,073		14,801		44,744		34,884
Other income, net	(3,240)		(1,028)		(15,303)		(1,462)
Income taxes	1,654		171		2,530		(541)
Equity income from unconsolidated joint ventures	(15,585)		(15,732)		(30,386)		(29,407)
Total discontinued operations	(1,559)		(75)		(2,121)		(3,181)
NOI	426,824		388,653		855,818		774,940
Straight-line rents	2,838		(11,860)		(15,955)		(21,787)
DFL accretion	(21,394)		(22,017)		(45,564)		(47,639)
Amortization of above and below market lease							
intangibles, net	(5,990)		(625)		(6,068)		(1,322)
Lease termination fees	(15)		(251)		(15)		(399)
NOI adjustments related to discontinued operations	(4)		479		(10)		1,109
Adjusted NOI	\$ 402,259	\$	354,379	\$	788,206	\$	704,902

The Company s total assets by segment were (in thousands):

June 30, December 31, Segments 2013